Cingulate Inc.

We are a biopharmaceutical company that develops next-generation pharmaceutical products using our proprietary Precision Timed Release ("PTR") drug delivery platform technology. Our goal is to improve the lives of patients with frequently diagnosed conditions that involve challenging daily dosing and less-than-ideal treatment results. We initially focus on treating Attention Deficit/Hyperactivity Disorder ("ADHD") and anxiety, and we are exploring other therapeutic areas where our PTR technology could be used for future product candidates. Our PTR platform features a proprietary Erosion Barrier Layer ("EBL") that allows drug substances to be released at specific, pre-defined time intervals, enabling once-daily, multi-dose tablets. We are targeting the ADHD treatment market, which is estimated to have approximately 100 million annual stimulant prescriptions in the US as of September 2025. The average wholesale acquisition cost (WAC) for branded long-acting stimulants is $495 per prescription. Stimulants are the most commonly prescribed class of medications for ADHD, accounting for approximately 90% of all ADHD medication prescriptions in the United States for the year ended September 30, 2025. Extended-release, or long-acting, stimulant medications are typically the first-line treatment for ADHD and are usually approved for once-daily morning dosing. However, many patients using current once-daily extended-release forms still require a second or "booster" dose later in the day, often in the early afternoon, to maintain active-day coverage, which can lead to unwanted side effects.